699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1).

Authors :: Rosenberg, J.E.
Galsky, M.D.
Balar, A.V.
Loriot, Y.
Necchi, A.
Hoffman-Censits, J.
Srinivas, S.
Drakaki, A.
Javery, A.
Nelson, B.
Huang, H.X.
Shen, X.
van der Heijden, M.S.
Source :: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS711-S712. 2p.
Publication Year :: 2021

Subjects :: *ATEZOLIZUMAB
*TRANSITIONAL cell carcinoma
*SURVIVAL analysis (Biometry)
*METASTASIS

Full Text Access

Tools